KRP-AM1977Y Phase II Clinical Study-To assess efficacy, safety and pharmacokinetics of KRP-AM1977Y in the patients with community acquired pneumonia

Trial Profile

KRP-AM1977Y Phase II Clinical Study-To assess efficacy, safety and pharmacokinetics of KRP-AM1977Y in the patients with community acquired pneumonia

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Lascufloxacin (Primary)
  • Indications Community-acquired pneumonia
  • Focus Therapeutic Use
  • Sponsors Kyorin Pharmaceutical
  • Most Recent Events

    • 25 Apr 2017 Results assessing the efficacy, safety, and pharmacokinetics of lascufloxacin intravenous infusion in patients with community acquired pneumonia, at the 27th European Congress of Clinical Microbiology and Infectious Diseases.
    • 01 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 14 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top